Fabry Disease Clinical Trial Patient Recruitment

Fabry disease patient recruitment for ERT, chaperone therapy, and substrate reduction clinical trials.

Who qualifies: Males and females with confirmed Fabry disease (GLA mutation) with or without prior ERT.

Recruitment challenges: GLA mutation confirmation and alpha-galactosidase A enzyme activity requirements.

Our approach: Metabolic disease center networks, Fabry patient registry access, and enzyme activity pre-screening.